Overview

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

Status:
Recruiting
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
A multicenter, open-label extension study evaluating the efficacy and safety of IBI311 in subjects with thyroid eye disease
Phase:
Phase 3
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.